0000000001198248

AUTHOR

Maria Gabriella Mazzucconi

showing 5 related works from this author

Activated prothrombin complex concentrate (FEIBA® ) in acquired haemophilia A: a large multicentre Italian study - the FAIR Registry

2019

MalePediatricsmedicine.medical_specialtyhaemophiliacoagulation factors030204 cardiovascular system & hematologyHemophilia AHaemophilia03 medical and health sciences0302 clinical medicineAcquired haemophiliaHumansMedicinecoagulation factorProspective StudiesRegistriesProspective cohort studyActivated prothrombin complex concentrateRetrospective Studiesbleeding disorders; coagulation factors; factor VIII; haemophilia; Blood Coagulation Factors; Female; Hemophilia A; Humans; Italy; Male; Prospective Studies; Retrospective Studies; Registriesbleeding disordersbleeding disorderbusiness.industryRetrospective cohort studyHematologymedicine.diseaseBlood Coagulation FactorsItalyfactor VIIIFemalebusiness030215 immunologyBritish Journal of Haematology
researchProduct

Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi® ) in the treatment of von Wille…

2002

Summary. The goal of therapy in patients with von Willebrand disease (vWD) is to correct the dual defect of primary haemostasis and intrinsic coagulation reflected by low levels of von Willebrand factor (vWF) and factor VIII coagulant activity (FVIII:C). Factor VIII/von Willebrand factor (FVIII/vWF) concentrates are currently the treatment of choice in vWD patients unresponsive to desmopressin (DDAVP). However, only few studies on their clinical use are available so far. The main objective of this study was to retrospectively evaluate the clinical efficacy of a highly purified, doubly virus-inactivated FVIII/vWF concentrate with a high content of FVIII/vWF (Fanhdi®). Twenty-two patients wit…

Excessive Bleedingcongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtybiologybusiness.industryRetrospective cohort studyHematologyGeneral Medicinemedicine.diseaseGastroenterologyVirusSurgeryVon Willebrand factorCoagulationhemic and lymphatic diseasesInternal medicinebiology.proteinVon Willebrand diseaseMedicinebusinessAdverse effectDesmopressinGenetics (clinical)medicine.drugHaemophilia
researchProduct

Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study

2005

researchProduct

Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management

2015

MaleAutoantibodies; Blood Coagulation Factor Inhibitors; Female; Humans; Male; Hemophilia A; Immunology and Allergy; HematologyBlood Coagulation Factor InhibitorsHumansImmunology and AllergyBlood Coagulation Factor InhibitorFemaleHematologyRecommendationHemophilia AAutoantibodieHumanAutoantibodies
researchProduct

Health-related quality of life and psychological well-being in elderly patients with haemophilia

2011

Many persons with severe haemophilia reach seniority thanks to effective treatment. There is no information on health-related quality of life (HRQoL) of these patients, who had lived for many years when regular replacement therapy was unavailable. Italian patients with severe haemophilia aged ≥65 years born in the 1940s or earlier were compared with men without bleeding disorders matched for age and geography. HRQoL was assessed via generic and disease-specific questionnaires. Potential associations with concomitant illnesses, orthopaedic status, physical functioning, cognitive status and depression were evaluated. In addition, the newly adapted HRQoL questionnaire specific for elderly pers…

MalePsychometricsHealth StatushaemophiliaComorbidityHemophilia AHemophilia BSettore MED/15 - Malattie Del SangueCross-Sectional StudiesItalyCase-Control StudiesSurveys and QuestionnairesActivities of Daily LivingQuality of LifeHumansFemaleAgedRetrospective Studies
researchProduct